{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:22Z","timestamp":1789948822835,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02891-2","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:03:29Z","timestamp":1789945409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation"],"prefix":"10.1038","volume":"11","author":[{"given":"Nan","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyong","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongling","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-9342","authenticated-orcid":false,"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2891_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"2891_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1378\/chest.128.1.452","volume":"128","author":"P Yang","year":"2005","unstructured":"Yang, P. et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 128, 452\u2013462 (2005).","journal-title":"Chest"},{"key":"2891_CR3","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919\u20131929 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2891_CR4","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel, D. R. et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J. Clin. Oncol. 40, 1301\u20131311 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2891_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 23, 209\u2013219 (2022).","journal-title":"Lancet Oncol."},{"key":"2891_CR6","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","volume":"32","author":"J Remon","year":"2021","unstructured":"Remon, J., Soria, J. C. & Peters, S. clinicalguidelines@esmo.org EGCEa. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann. Oncol. 32, 1637\u20131642 (2021).","journal-title":"Ann. Oncol."},{"key":"2891_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1515\/jtim-2025-0047","volume":"13","author":"W Wang","year":"2025","unstructured":"Wang, W. et al. Protocol for Chinese lung cancer evolution and microenvironment tracking under therapy study. J. Transl. Int. Med. 13, 599\u2013609 (2025).","journal-title":"J. Transl. Int. Med."},{"key":"2891_CR8","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1016\/j.cllc.2019.02.021","volume":"20","author":"M Nakamura","year":"2019","unstructured":"Nakamura, M. et al. Impact of EGFR mutation and ALK translocation on recurrence pattern after definitive chemoradiotherapy for inoperable stage III non-squamous non-small-cell lung cancer. Clin. Lung Cancer 20, e256\u2013e264 (2019).","journal-title":"Clin. Lung Cancer"},{"key":"2891_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ajco.13940","volume":"20","author":"U Nindra","year":"2024","unstructured":"Nindra, U. et al. Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab. Asia Pac. J. Clin. Oncol. 20, 16\u201324 (2024).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"2891_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jtho.2023.02.009","volume":"18","author":"J Naidoo","year":"2023","unstructured":"Naidoo, J. et al. Brief report: durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC: a post hoc subgroup analysis from PACIFIC. J. Thorac. Oncol. 18, 657\u2013663 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"2891_CR11","doi-asserted-by":"crossref","unstructured":"Lu, S. et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N. Engl. J. Med. 39, 585\u2013597 (2024).","DOI":"10.1056\/NEJMoa2402614"},{"key":"2891_CR12","unstructured":"Meng, X. et al. Aumolertinib After Chemoradiotherapy in Unresectable Stage lll Non-small-cell Lung Cancer with EGFR Mutation: Interim Analysis of the Phase lll POLESTAR Study (World Congress of Lung Cancer, San Diego, 2024)."},{"key":"2891_CR13","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.jtho.2021.05.019","volume":"16","author":"H Akamatsu","year":"2021","unstructured":"Akamatsu, H. et al. Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced NSCLC With EGFR mutation; West Japan Oncology Group 6911L. J. Thorac. Oncol. 16, 1745\u20131752 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2891_CR14","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.ijrobp.2020.11.026","volume":"109","author":"L Xing","year":"2021","unstructured":"Xing, L. et al. Erlotinib versus etoposide\/cisplatin with radiation therapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small cell lung cancer: a multicenter, randomized, open-label, phase 2 trial. Int. J. Radiat. Oncol. Biol. Phys. 109, 1349\u20131358 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2891_CR15","first-page":"65","volume":"3","author":"N Bi","year":"2023","unstructured":"Bi, N. et al. Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: a multi-center cohort study. J. Natl. Cancer Cent. 3, 65\u201371 (2023).","journal-title":"J. Natl. Cancer Cent."},{"key":"2891_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi, M. et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N. Engl. J. Med 389, 137\u2013147 (2023).","journal-title":"N. Engl. J. Med"},{"key":"2891_CR17","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","volume":"28","author":"A Auperin","year":"2010","unstructured":"Auperin, A. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 2181\u20132190 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2891_CR18","doi-asserted-by":"crossref","unstructured":"O\u2019Rourke, N., Roque, I. F. M., Farre Bernado, N. & Macbeth, F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst. Rev.CD002140 (2010).","DOI":"10.1002\/14651858.CD002140.pub3"},{"key":"2891_CR19","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1158\/1078-0432.CCR-07-1606","volume":"14","author":"T Tanaka","year":"2008","unstructured":"Tanaka, T. et al. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin. Cancer Res. 14, 1266\u20131273 (2008).","journal-title":"Clin. Cancer Res."},{"key":"2891_CR20","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.1158\/0008-5472.CAN-11-0213","volume":"71","author":"M Wang","year":"2011","unstructured":"Wang, M. et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res. 71, 6261\u20136269 (2011).","journal-title":"Cancer Res."},{"key":"2891_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2891_CR22","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947\u2013957 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2891_CR23","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO-25-00883","volume":"43","author":"J He","year":"2025","unstructured":"He, J. et al. Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer. J. Clin. Oncol. 43, 2875\u20132887 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2891_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","volume":"33","author":"A Passaro","year":"2022","unstructured":"Passaro, A. et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann. Oncol. 33, 466\u2013487 (2022).","journal-title":"Ann. Oncol."},{"key":"2891_CR25","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1200\/JCO.23.02746","volume":"42","author":"IA Jaiyesimi","year":"2024","unstructured":"Jaiyesimi, I. A. et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2023.3. J. Clin. Oncol. 42, e23\u2013e43 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2891_CR26","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1200\/JCO.23.02744","volume":"42","author":"IA Jaiyesimi","year":"2024","unstructured":"Jaiyesimi, I. A. et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2023.3. J. Clin. Oncol. 42, e1\u2013e22 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2891_CR27","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/1759-7714.13816","volume":"12","author":"K Xu","year":"2021","unstructured":"Xu, K. et al. Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. Thorac. Cancer 12, 814\u2013823 (2021).","journal-title":"Thorac. Cancer"},{"key":"2891_CR28","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J. Clin. Oncol. 40, 3162\u20133171 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2891_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jtho.2021.10.024","volume":"17","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results from the APOLLO Registrational Trial. J. Thorac. Oncol. 17, 411\u2013422 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"2891_CR30","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.jtho.2021.01.1628","volume":"16","author":"JV Aredo","year":"2021","unstructured":"Aredo, J. V. et al. Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy. J. Thorac. Oncol. 16, 1030\u20131041 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2891_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","volume":"16","author":"JC Yang","year":"2015","unstructured":"Yang, J. C. et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 16, 141\u2013151 (2015).","journal-title":"Lancet Oncol."},{"key":"2891_CR32","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ijrobp.2022.12.042","volume":"116","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Induction immune checkpoint inhibitors and chemotherapy before definitive chemoradiation therapy for patients with bulky unresectable stage III non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 116, 590\u2013600 (2023).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2891_CR33","first-page":"881","volume":"41","author":"Chinese Anti-Cancer Association CoLCS","year":"2019","unstructured":"Chinese Anti-Cancer Association CoLCS Lung Cancer Group of Oncology Branch CMA. [Chinese expert consensus on the multidisciplinary clinical diagnosis and treatment of stage \u2162 non-small cell lung cancer (2019)]. Zhong Liu Za Zhi 41, 881\u2013890 (2019).","journal-title":"Zhong Liu Za Zhi"},{"key":"2891_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2022.02.014","volume":"167","author":"M Riudavets","year":"2022","unstructured":"Riudavets, M. et al. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. Eur. J. Cancer 167, 142\u2013148 (2022).","journal-title":"Eur. J. Cancer"},{"key":"2891_CR35","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jtho.2024.01.012","volume":"19","author":"AH Nassar","year":"2024","unstructured":"Nassar, A. H. et al. Consolidation osimertinib versus durvalumab versus observation after concurrent chemoradiation in unresectable EGFR-mutant NSCLC: a Multicenter Retrospective Cohort Study. J. Thorac. Oncol. 19, 928\u2013940 (2024).","journal-title":"J. Thorac. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02891-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02891-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02891-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:03:31Z","timestamp":1789945411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02891-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2891"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02891-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. The ADVANCE trial was an investigator-initiated trial, and the Jiangsu Hansoh Pharmaceutical Group Co., Ltd provided aumolertinib and chemotherapy agents in this trial.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"395"}}